100mg 200mg
50mg

Avanafil Tablets
Afa' nafei Pian

4-[3- -4-]-2-[2S -2-
-1-]-N- -2- -5-



$C_{23}H_{26}ClN_7O_3$
483.95

1 100mg 2 200mg

100mg 15
200mg 15
50mg 30

1

2 α
α
α 50mg

3 CYP3A4
CYP3A4

CYP3A4

50mg 24 1

2215
493 6
153 12
3 3
56.4 23~88 83.9% 13.8% 1.4%
1% 41.1% 30.6%
50mg 100mg 200mg
1.4% 2.0% 2.0% 1.7%
1 3

1. 3 3
≥ 2%

	N=349	50mg N 217	100mg N 349	200mg N 352
	1.7%	5.1%	6.9%	10.5%
	0.0%	3.2%	4.3%	4.0%
	1.1%	1.8%	2.9%	2.0%
	2.9%	0.9%	2.6%	3.4%
	1.1%	3.2%	2.0%	1.1%

≥ 1% 2%
URI

2
52 712
56.4 23~88 50mg 100mg
200mg 2.8%

100mg
200mg 50mg 536 75%
200mg 5 1% 50mg
2

2. ≥ 2%

	(N=711)
	5.6%
	3.5%
	3.4%
	2.1%

≥ 1% 2%
URI
3 3 / 12
1%

3 298
58.4 40~70
3

3. 3 ≥ 2%

	N 100	100mg N 99	200mg N 99
	1.0%	8.1%	12.1%
	0.0%	5.1%	10.1%
	0.0%	3.0%	5.1%
	0.0%	2.0%	3.0%
	1.0%	3.0%	1.0%
	1.0%	3.0%	2.0%
	0.0%	1.0%	3.0%
	0.0%	1.0%	2.0%

2 435
58.2 24~86
4
≥ 2%
4 2
≥ 2%

	N=143	100mg N=146	200mg N=146
	0.7%	1.4%	8.9%
	0.0%	0.7%	4.1%
	0.0%	0.0%	2.1%

1

NAION
5 PDE5
NAION
NAION
" " 50

1. /
/ cGMP
12

2.

3. GC
GC PDE5
GC

4.
6
<90/50 mmHg >170/100 mmHg
2

5. Child-Pugh C
<30 ml/min

6. NAION
PDE5

7.

8. CYP3A4

1.
PDE5
200mg
8.0mmHg 3.3mmHg 1

2. CYP3A4
CYP450 3A4 CYP3A4 CYP3A4
CYP3A4

CYP3A4
50mg 24 1

3.
PDE5 4
6 4

Peyronie

4.
PDE5
NAION NAION
PDE5
NAION ≥ 50
NAION 2.5~11.8/10
NAION PDE5
5 PDE5 NAION
NAION 2
2.15 95%CI 1.06 4.34
2.27 95%CI 0.99 5.20 NAION "
" NAION
PDE5
NAION PDE5 NAION
PDE5 NAION
NAION NAION
PDE5
" "
NAION
PDE5

5.
PDE5
PDE5

6. α
α
PDE5 α PDE5
α-

- PDE5 α
α
PDE5
- α PDE5
50mg
- PDE5 α
PDE5 α

PDE5 α

7.
PDE5
3

8. PDE5

9.
[NO]

10.
HIV

18

65 23% 65

1.

12